Saranas Recognized as One of Houston’s Most Innovative Companies
Houston, TX — August 14, 2019 — Saranas Inc., a medical device company pioneering technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been named one of Houston’s most innovative companies. Saranas is the only medical device company to be honored at the inaugural Innovation Awards presentation sponsored by the Houston Business Journal on September
Innovation honorees were selected by a panel of judges based upon their demonstrated success in innovation in the past 16 to 18 months. During this time, Saranas was granted de novo classification by the U.S. Food and Drug Administration (FDA) for their Early Bird®Bleed Monitoring System. Additionally, the company presented ‘first in human’ results at the Society for Cardiovascular Angiography Interventions (SCAI) Scientific Sessions, demonstrating that the Early Bird device is effective in early detection of internal bleeding.
One in five patients experience a bleeding complication during large-bore endovascular procedures such as transcatheter aortic valve replacement (TAVR), endovascular aneurysm repair (EVAR) and percutaneous mechanical circulatory support. The Early Bird is the first and only device for real-time detection and monitoring of these types of complications.
“We are honored to be recognized as a leader in Houston’s rapidly expanding innovation ecosystem,” said Saranas President and CEO, Zaffer Syed. “We believe that the Early Bird is an important technology advancement that will significantly reduce bleeding complications and related healthcare costs, while improving clinical outcomes in patients undergoing endovascular procedures.”
Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications.
The company’s patented Early Bird Bleed Monitoring System for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more information, please visit www.saranas.com.